0001193125-26-209179
SEC filingRevenue surged on a milestone payment, but net loss widened dramatically due to non-cash fair value adjustments on liabilities.
Revenue jumped to $5.0M from $983K in the prior-year quarter, entirely driven by a $5.0M milestone payment from Boehringer Ingelheim under the Collaboration and License Agreement for SZN-413. This milestone was triggered by a positive outcome in IND-enabling GLP toxicology studies, reflecting continued progress in the partnered ophthalmology program. The prior-year revenue came from research services under a now-terminated agreement with TCGFB, Inc., which contributed $983K. The shift from recurring service revenue to milestone-based collaboration revenue underscores Surrozen's transition toward a development-stage biotech model, where revenue is lumpy and tied to clinical and regulatory achievements.
Net loss for the quarter was $127.5M, compared to $27.0M in the prior year. The increase was primarily driven by non-cash fair value adjustments on liabilities, including a loss on tranche liability and a loss on warrant liabilities. These adjustments are accounting-driven and do not affect cash flows. Operating loss widened 9.5% to $10.5M, reflecting higher research and development expenses as the company advanced its pipeline, as well as increased general and administrative costs. The company expects expenses to continue to increase as it progresses product candidates through clinical development and regulatory approval.
Net cash used in operating activities was $12.5M, compared to $9.3M in the prior year, reflecting increased spending on R&D and pre-clinical activities. Capital expenditures were $120K, up from $27K, primarily for lab equipment. Free cash flow was negative $12.6M. The company has historically funded operations through equity offerings and collaboration agreements. Management notes that the company will continue to require substantial additional capital to develop product candidates and fund operations for the foreseeable future. The company expects operating expenses to remain significant as it prepares for clinical studies and anticipates the need to raise additional capital to execute its long-range business plan.
Since inception, Surrozen has generated revenue only from licensing and research collaborations. The company has incurred significant operating losses and negative cash flows from operations. Management cautions that projections of operating capital requirements are based on assumptions that may prove incorrect, and the company may use all available capital resources sooner than expected. Due to the numerous risks and uncertainties associated with pharmaceutical development, the exact amount of operating capital requirements cannot be estimated. Inflation has increased and is expected to continue, which may impact costs. The company's ability to continue as a going concern is dependent on its ability to raise additional capital.